Boehringer Ingelheim Atrial Fibrillation symposium focuses on stroke threats in UAE
- United Arab Emirates: Thursday, March 07 - 2013 at 10:21
- PRESS RELEASE
A scientific symposium was conducted by Boehringer Ingelheim highlighted the threats of storks resulting from Atrial Fibrillation (AF) in the UAE.
One in four adults over the age of 40 develop AF in their lifetime, resulting in 4.5 million people suffering from AF in Europe. AF patients have a five times increased risk of suffering a stroke, resulting in three million people worldwide having AF-related strokes each year. Patients with AF have been shown to have a worse quality of life than for example patients who have previously suffered a heart attack, due to the constant fear of suffering from a stroke.
Dr. Michael D. Ezekowitz, Director of Atrial Fibrillation Research & Education at Cardiovascular Research Foundation, commented, "AF is a major risk factor for stroke as it allows pooling of blood in the heart, causing blood clots to form. By travelling up to the vessels in the brain and blocking them, these clots can cause a stroke. Strokes from AF are particularly devastating as the clots are often very big, obstructing large vessels of the brain. This leads to greater disability, such as more severe loss of muscle function or loss of speech."
Dr. Arif Al-Mulla, Head of Cardiology at Dubai Hospital, alerted the participants saying, "The symposium is a platform to highlight what is one of the biggest health concerns of the current century. Atrial Fibrillation is the most common arrhythmia worldwide and is also a common cause of hospital admission in the Gulf region. In 2011, AF was the primary reason for the ER visits in 45% of patients in the Gulf region".
There has been recent increased interest in AF because of the expected rise in its prevalence, the greater appreciation of its serious outcomes, and the development of new anticoagulant and antiarrhythmic medications for its management.
"The new era of anti coagulants and blood thinners as medications for Atrial Fibrillation had overcome the old medication's limitations such as the need for regular monitoring and various food-drug and drug-drug interactions", said Dr. Mohamed Meshref, Medical Director for Middle East and North Africa at Boehringer Ingelheim.
During the symposium the discussion tackled issues related to challenges of treating AF patients, medical advancement of the new oral anti-coagulants for stroke prevention in AF and the usage of the new medications.
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of Mediaquest FZ LLC. Mediaquest FZ LLC is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.